CD30 CAR T-cell therapy promoted a prolonged remission in a patient with multiply relapsed EATL.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7724914 | PMC |
| http://dx.doi.org/10.1182/bloodadvances.2020003218 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Rate of response to immune checkpoint inhibitor therapy in patients with conjunctival melanoma.
Melanoma Res
December 2024
Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Our primary objective was to estimate the overall response rate to immune checkpoint inhibitors (ICIs) in patients with locally advanced, multiply recurrent, or metastatic conjunctival melanoma treated with ICIs. A retrospective review of all consecutive conjunctival melanoma patients who were treated with ICI between October 2017 and January 2024 was carried out. The study included 16 patients with a median age of 66 years.
View Article and Find Full Text PDFRelapse-free survival is progressively shortened in a subset of Black patients with immune-mediated TTP treated in the rituximab era.
Blood Adv
January 2025
Department of Medicine, Johns Hopkins University, Baltimore, MD.
Article Synopsis
- - Immune thrombotic thrombocytopenic purpura (iTTP) is a serious condition involving low platelet counts due to a deficiency in the enzyme ADAMTS13, often treated with rituximab to prevent relapses.
- - A study using data from the USTMA registry found that the time without relapse (relapse-free survival or RFS) decreased after each rituximab treatment, particularly for Black patients, suggesting that the effectiveness of the drug diminishes with repeated use.
- - Both the USTMA registry and a separate cohort from Johns Hopkins and the University of Minnesota indicated that Black patients experience a significantly higher risk of relapse with subsequent rituximab treatments, implying a need
A successful application of information technologies in the treatment of multiple sclerosis: a case report.
J Med Case Rep
November 2024
Microbiology, Infectious and Parasitic Diseases, The Research Institute of Virology of the National Specialized Scientific and Practical Medical Center for Epidemiology, 7A Yangi Shahar Street, 100194, Tashkent, Uzbekistan.
Background: Multiple sclerosis is a chronic disease of the central nervous system characterized by inflammation, neurodegeneration, and failure of the central nervous system's repair mechanisms. The role of infectious agents against the background of genetic predisposition is currently considered a possible pathogenesis factor of this disease.
Case Presentation: We report the case of a 52-year-old white (Russian) female musician with 15-year history of relapsing-remitting multiple sclerosis who had repeatedly received conventional therapy without much benefit.
The evolving role of checkpoint inhibitors in the treatment of Hodgkin lymphoma.
Front Oncol
October 2024
Washington University School of Medicine, Siteman Cancer Center, St. Louis, MO, United States.
Since their initial approval as single agent therapy for multiply relapsed/refractory Hodgkin lymphoma (HL), the PD-1 inhibitors nivolumab and pembrolizumab have been incorporated into second-line salvage regimens, and they are being investigated in upfront therapy of newly diagnosed patients. As second-line therapy in combination with brentuximab vedotin or multi-agent chemotherapy, nivolumab and pembrolizumab provide high complete remission rates and durable progression-free survival after consolidative autologous stem cell transplant. Incorporation of these agents into frontline chemotherapy regimens is feasible, and early results from a Phase III trial of nivolumab-AVD compare favorably with the existing standard for advanced stage HL, brentuximab vedotin plus AVD.
View Article and Find Full Text PDFChanges in insomnia and binge-eating symptom severity before and after treatment of eating disorders in individuals with non-low-weight binge-spectrum disorders.
J Sleep Res
November 2024
Department of Psychology, University of Kansas, Lawrence, Kansas, USA.
Article Synopsis
- Research indicates a strong association between insomnia and binge eating symptoms among college students with eating disorders, suggesting that insomnia may contribute to eating disorder severity.
- Although treatment reduced insomnia symptoms modestly, approximately 50% of participants with significant insomnia at the start of treatment continued to experience sleep issues post-treatment.
- Future research is necessary to explore the causal relationship between insomnia and eating disorders and to investigate effective treatments addressing both conditions.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!